149 related articles for article (PubMed ID: 32696934)
1. Clinical and epidemiological characteristics of M. kansasii pulmonary infections from Rio de Janeiro, Brazil, between 2006 and 2016.
Goldenberg T; Gayoso R; Mogami R; Lourenço MC; Ramos JP; Carvalho LD; Dalcolmo MP; Mello FCQ
J Bras Pneumol; 2020; 46(6):e20190345. PubMed ID: 32696934
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
[TBL] [Abstract][Full Text] [Related]
4. [Nontuberculous mycobacterial infections of the lung].
Latshang TD; Lo Cascio CM; Russi EW
Ther Umsch; 2011 Jul; 68(7):402-6. PubMed ID: 21728159
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
[TBL] [Abstract][Full Text] [Related]
7. Mycobacterium kansasii.
Johnston JC; Chiang L; Elwood K
Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28185617
[TBL] [Abstract][Full Text] [Related]
8. [Pain, swelling, and progressive weakness of the left knee over 6 years].
Pelfort X; Horcajada JP; Puig L; Salvadó M
Enferm Infecc Microbiol Clin; 2008 Nov; 26(9):595-6. PubMed ID: 19100182
[No Abstract] [Full Text] [Related]
9. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
10. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment.
Jenkins PA; Campbell IA;
Respir Med; 2003 Apr; 97(4):439-44. PubMed ID: 12693807
[TBL] [Abstract][Full Text] [Related]
11. [Fever and thin-walled cavitary lung lesions].
Ramos A; Daza R; Alvarez-Espejo T; Guzmán MF
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):363-4. PubMed ID: 19419797
[No Abstract] [Full Text] [Related]
12. Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient.
Cosson MA; Bertrand JB; Martin C; Veziris N; Picard C; Goulvestre C; Coignard S; Benoit JP; Silvera S; Moro MR; Poyart C; Morand PC
J Med Microbiol; 2012 Nov; 61(Pt 11):1617-1620. PubMed ID: 22859583
[TBL] [Abstract][Full Text] [Related]
13. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Research Committee of the British Thoracic Society
Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterium kansasii pulmonary diseases in Korea.
Yim JJ; Park YK; Lew WJ; Bai GH; Han SK; Shim YS
J Korean Med Sci; 2005 Dec; 20(6):957-60. PubMed ID: 16361804
[TBL] [Abstract][Full Text] [Related]
15. [THE GENETIC EXAMINATION OF BRONCHIAL LAVAGE ENABLES THE PROMPT DIAGNOSIS OF PULMONARY MYCOBACTERIUM KANSASII--A CASE REPORT].
Mori M; Ageshio F; Kagawa H; Oshitani Y; Fujikawa T; Saito H; Sako H; Yano Y; Kitada S; Maekura R
Kekkaku; 2015 Aug; 90(8):619-23. PubMed ID: 26665518
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea.
Park HK; Koh WJ; Shim TS; Kwon OJ
Yonsei Med J; 2010 Jul; 51(4):552-6. PubMed ID: 20499421
[TBL] [Abstract][Full Text] [Related]
17. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
[TBL] [Abstract][Full Text] [Related]
18. [Swelling of right knee in an immunologically compromised patient].
Cajigas-Pezo D; Lorenzo-Hernandez A; Vives-Rivero GR; Rentero-Martínez Z
Enferm Infecc Microbiol Clin; 2012 Oct; 30(8):481-2. PubMed ID: 22521279
[No Abstract] [Full Text] [Related]
19. [Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS].
Ibarrola M; Baraia-Etxaburu J; Sánchez R; Teira R; Unzaga J; Miguel Santamaría J
Enferm Infecc Microbiol Clin; 2001 Feb; 19(2):80-2. PubMed ID: 11333577
[No Abstract] [Full Text] [Related]
20. [Distribution and drug resistance of nontuberculous
Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
[No Abstract] [Full Text] [Related]
[Next] [New Search]
